ARTICLE | Finance
CellCentric’s magic trio
Why Morningside is backing CellCentric’s single-asset strategy
May 18, 2018 8:40 PM UTC
Five years after pivoting from target discovery to drug development, epigenetics play CellCentric Ltd. is taking its sole asset CCS1477 into the clinic next month with $26 million from Morningside Venture Investments. The company believes the undisclosed venture round will be enough to get the prostate cancer compound through clinical proof-of-concept studies.
Morningside first invested in CellCentric in 2007...
BCIQ Company Profiles